Latest Breaking News On - Kenji yasukawa - Page 5 : comparemela.com

Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, "Astellas"), Eisai Co., Ltd. (TSE: 4523, CEO: Haruo Naito, "Eisai"),.

Haruo naitoKenji yasukawaChristophe weberDaiichi sankyoSunao manabeDaiichi sankyo companySustainability environment of each companyTakeda pharmaceutical companySustainable development of societyEisai co ltdAstellas pharma incInnovative global healthcare companyUnited nations sustainable development goals sdgsPrnewswire astellas pharma incCorporate strategic planEnvironmental management

Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 GLOW Trial as First-Line Treatment in Claudin 18 2 Positive, HER2-negative Locally Advanced Unresectable or Metastatic Gastric and Gas

Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 GLOW Trial as First-Line Treatment in Claudin 18 2 Positive, HER2-negative Locally Advanced Unresectable or Metastatic Gastric and Gas
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomRuihua xuKenji yasukawaAhsan arozullahNational cancer instituteSun yat sen university cancer centerDepartment of medical oncologyEnd results programAstellas pharma incAstellasastellas pharma incHead of development therapeutic areasPrnewswire astellas pharma incAmerican cancer societyPrimary investigatorMedical oncology

Astellas and MBC BioLabs Announce 2022 Future Innovator Prize Awarded to Bespoke Biotherapeutics and Cellinfinity Bio

/PRNewswire/ Astellas Venture Management LLC (President: William Watt, Ph.D., "AVM"), a wholly-owned venture capital subsidiary of Astellas Pharma Inc..

San franciscoUnited statesSan carlosKenji yasukawaStevenr deitcherCellinfinity bioPremal patelDouglas crawfordWilliam wattPrnewswire astellas venture managementAstellas pharma incAstellas venture managementMission biocapital biolabsMission biocapitalBoth companieswinAstellas pharma

Astellas and MBC BioLabs Announce 2022 Future Innovator Prize Awarded to Bespoke Biotherapeutics and Cellinfinity Bio

/PRNewswire/ Astellas Venture Management LLC (President: William Watt, Ph.D., "AVM"), a wholly-owned venture capital subsidiary of Astellas Pharma Inc..

San franciscoUnited statesSan carlosKenji yasukawaStevenr deitcherCellinfinity bioPremal patelDouglas crawfordWilliam wattPrnewswire astellas venture managementAstellas pharma incAstellas venture managementMission biocapital biolabsMission biocapitalBoth companieswinAstellas pharma

Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as First-Line Treatment in Claudin 18 2 Positive, HER2-Negative Locally Advanced or Metastatic Gastric and Gastroesophageal Junction (GEJ) Cancers

Zolbetuximab is an investigational first-in-class monoclonal antibody targeting Claudin 18.2 (CLDN18.2), for the first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

United statesUnited kingdomKenji yasukawaAhsan arozullahKohei shitaraNational cancer center hospitalAstellas pharma incEnd results programNational cancer instituteHead of development therapeutic areasDepartment of gastrointestinal oncologyAmerican cancer societyPrimary investigatorGastrointestinal oncologyNational cancer center hospital eastSenior vice president